

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7900738

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
SPROUT PHARMACEUTICALS, INC.	03/31/2023
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ANNE HOLLAND
<b>Street Address:</b>	4350 LASSITER AT NORTH HILLS AVE., STE. 260
<b>City:</b>	RALEIGH
<b>State/Country:</b>	NORTH CAROLINA
<b>Postal Code:</b>	27609
<b>Name:</b>	SANDRA MCGLOTHLIN
<b>Street Address:</b>	4350 LASSITER AT NORTH HILLS AVE., STE. 260
<b>City:</b>	RALEIGH
<b>State/Country:</b>	NORTH CAROLINA
<b>Postal Code:</b>	27609
<b>PROPERTY NUMBERS Total: 9</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17101961
Patent Number:	7151103
Patent Number:	8227476
Patent Number:	8785458
Patent Number:	9730927
Patent Number:	10335407
Patent Number:	10874668
Patent Number:	10596170
Patent Number:	10166230
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(919)755-2150
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	9197558164
<b>Email:</b>	diann.gravius@wbd-us.com

<b>Correspondent Name:</b>	JESSICA L. GORCZYNSKI
<b>Address Line 1:</b>	555 FAYETTEVILLE STREET
<b>Address Line 2:</b>	WOMBLE BOND DICKINSON (US) LLP
<b>Address Line 4:</b>	RALEIGH, NORTH CAROLINA 27601

<b>ATTORNEY DOCKET NUMBER:</b>	S107088 0001.9
--------------------------------	----------------

<b>NAME OF SUBMITTER:</b>	JESSICA L. GORCZYNSKI
---------------------------	-----------------------

<b>SIGNATURE:</b>	/jessica l. gorczynski/
-------------------	-------------------------

<b>DATE SIGNED:</b>	04/13/2023
---------------------	------------

**Total Attachments: 4**

source=Sprout2\_Patent\_Security\_Agreement\_March\_2023#page1.tif

source=Sprout2\_Patent\_Security\_Agreement\_March\_2023#page2.tif

source=Sprout2\_Patent\_Security\_Agreement\_March\_2023#page3.tif

source=Sprout2\_Patent\_Security\_Agreement\_March\_2023#page4.tif

**PATENT SECURITY AGREEMENT**

This PATENT SECURITY AGREEMENT (this "Agreement"), dated as of March 31, 2023, is entered into by Sprout Pharmaceuticals, Inc., a Delaware corporation (the "Grantor"), and Anne Holland and Sandra McGlothlin (each, a "Purchaser Representative" and collectively, the "Purchaser Representatives"), on behalf of the Purchasers (the Purchasers, collectively, the "Secured Party").

Capitalized terms not otherwise defined herein have the meanings set forth in the Security Agreement dated as of March 31, 2023, among the Grantor, Sprout2, Inc., the Purchaser Representatives and the Purchasers.

WHEREAS, pursuant to the Security Agreement, the Grantor has granted a security interest to the Secured Party in certain Patents whether now owned or existing or hereafter acquired or arising and wherever located, including without limitation the patents listed on Schedule A ("Secured Patents").

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantor and the Secured Party hereby agree as follows:

(i) Grant of Security Interest.

(a) The Grantor hereby grants to the Secured Party a security interest in, and continuing lien on, all of the Grantor's right, title and interest in, to and under all the Secured Patents, subject to the terms and conditions of the Security Agreement.

(b) The security interest granted hereby is granted in conjunction with the security interest granted to the Secured Party under the Security Agreement. The rights and remedies of the Secured Party with respect to the security interest granted hereby are in addition to those set forth in the Security Agreement. In the event of any conflict between the terms of this Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall control.

(c) The Grantor and Secured Party hereby acknowledge and agree that the security interest in the Secured Patents is not to be construed as an assignment of any patent or patent application.

(ii) Governing Law.

**THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE.**

(iii) Successors and Assigns.

This Agreement shall be binding upon and inure to the benefit of the Secured Party and the Grantor and their respective successors and assigns. The Grantor shall not, without the prior written consent of the Secured Party, assign any right, duty or obligation hereunder.

(iv) Counterparts.

This Agreement may be executed in any number of counterparts and by the parties hereto on separate counterparts, each of which when so executed, shall be deemed to be an original and all of which taken together shall constitute one and the same instrument.

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the Grantor and the Secured Party have caused this Patent Security Agreement to be duly executed and delivered as of the date first above written.

**GRANTOR:**

**Sprout Pharmaceuticals, Inc.,**  
a Delaware corporation

By: Matthew Petzold  
Name: Matthew Petzold  
Title: Chief Financial Officer

**PURCHASER REPRESENTATIVES:**

By: Elizabeth Anne Holland  
Name: Anne Holland

By: Sandra McGlothlin  
Name: Sandra McGlothlin

## SCHEDULE A

## PATENT SECURITY AGREEMENT

## 1. U.S. Registered Patents

Title	Country	Patent Number	Expiration Date
<b><i>Treating Sexual Desire Disorders with Flibanserin</i></b>			
	United States	7,151,103	9-May-28
<b><i>Flibanserin in the Treatment of Obesity</i></b>			
	United States	8,227,476	31-Jul-26
	United States	8,785,458	31-Jul-26
	United States	9,730,927	31-Jul-26
	United States	10,335,407	31-Jul-26
	United States	10,874,668	31-Jul-26
<b><i>Treatment of Vasomotor Symptoms</i></b>			
	United States	10,596,170	11-Sep-28
	United States	10,166,230	11-Sep-28

## 2. U.S. Pending Patent Applications

Title	Country	Application Number	Filing Date
<b><i>Use of Flibanserin in the Treatment of Obesity</i></b>			
	United States	17/101,961	23-Nov-20